Last updated: September 1, 2026
Mebendazole is a mature, low-cost anthelmintic with stable public-health demand and limited branded growth potential. Its commercial value is driven by volume, procurement contracts, formulation access, and regional disease burden rather than innovation-based pricing. The U.S. market has experienced a split between inexpensive generic tablets and higher-priced branded or authorized-generic presentations. No major pharmaceutical company publicly reports standalone global mebendazole revenue, so the financial trajectory must be assessed through product approvals, pricing structure, market access, and generic competition.
What is the current market position of mebendazole?
Mebendazole is a benzimidazole antiparasitic used primarily for intestinal worm infections, including pinworm, roundworm, whipworm, and hookworm infections. It is listed on the World Health Organization Model List of Essential Medicines and is used in mass drug administration and routine clinical treatment programs.[1]
| Market factor |
Current position |
| Active ingredient |
Mebendazole |
| Main therapeutic category |
Anthelmintic |
| Principal indications |
Enterobiasis, ascariasis, trichuriasis, hookworm and related helminth infections |
| Common dosage form |
100 mg chewable tablet |
| Prescription status |
Varies by country; generally prescription or pharmacist-controlled |
| Major demand sources |
Public-health procurement, pediatric treatment, outpatient prescriptions |
| Commercial maturity |
Mature generic market |
| Biosimilar exposure |
None; mebendazole is a small-molecule drug |
| Primary competitive pressure |
Generic manufacturers and low-cost public-sector suppliers |
| Innovation potential |
Limited for the approved antiparasitic indication |
Demand is relatively defensive because treatment is inexpensive, short-course and linked to endemic infection rates. Sales growth is constrained by the low price per treatment and the availability of alternative anthelmintics, particularly albendazole and pyrantel products.
How large is the mebendazole market?
There is no consolidated, audited market figure for global mebendazole sales. Commercial market-research estimates vary widely because they use different definitions of the market. Some count only finished-dose products; others include albendazole, ivermectin and other antiparasitics in a broader anthelmintic category.
A defensible financial assessment separates the market into four segments:
- Retail and outpatient prescriptions in North America and Europe.
- Pediatric and family treatment in middle-income countries.
- Government and nongovernmental-organization procurement.
- Hospital and institutional supply, including endemic-region programs.
The largest unit volumes are likely generated in countries with high intestinal parasite prevalence and active deworming programs. The highest nominal prices are generally found in regulated retail markets, where branded or limited-competition presentations can command a premium over public-sector tenders.
The market is therefore volume-heavy but revenue-light. A manufacturer can achieve meaningful unit sales without generating the revenue associated with newer anti-infective or chronic-disease products.
What drives mebendazole demand?
Public-health and endemic disease demand
The World Health Organization recommends periodic deworming in areas where soil-transmitted helminth infections are common and prevalence thresholds justify treatment.[2] This creates recurring demand through national programs, school-based treatment and community distribution.
Demand depends on:
- Infection prevalence.
- Government health budgets.
- Procurement cycles.
- School and community treatment policies.
- Availability of competing anthelmintics.
- Local manufacturing and tender participation.
Mebendazole is particularly relevant where a low-cost oral tablet is preferred and cold-chain logistics are not practical.
Retail and pediatric demand
The 100 mg chewable tablet is commercially important because it supports treatment of children and simplifies administration. Pediatric demand is recurring but episodic, with sales often concentrated around school health campaigns, family treatment events and seasonal prescribing patterns.
Off-label and investigational demand
Mebendazole has been investigated for oncology and other non-parasitic conditions. These uses have not created an approved, large-scale commercial market. Evidence from laboratory, animal and early clinical research does not establish a revenue stream comparable to the approved antiparasitic market.[3]
Off-label interest can increase media attention and small-volume prescribing, but it does not materially change the base-case financial outlook without regulatory approval, clinical validation and reimbursement.
What is the financial trajectory for mebendazole?
Mebendazole follows the typical financial profile of a mature generic medicine:
| Stage |
Financial characteristics |
| Early branded period |
Higher prices, limited competition and greater product differentiation |
| Generic expansion |
Price erosion, more suppliers and reduced gross margins |
| Mature market |
Stable unit demand, low per-unit revenue and procurement-driven pricing |
| Shortage or supplier exit |
Temporary price increases and supply volatility |
| Long-term outlook |
Low-to-moderate volume growth with limited value growth |
Revenue trajectory is likely to be flat to modestly positive in established markets, with growth coming primarily from population expansion, diagnosis, public-health programs and geographic penetration. Price-driven revenue growth is difficult to sustain because the drug has been available for decades and has limited formulation complexity.
Profitability can still be attractive for manufacturers with:
- Low-cost active pharmaceutical ingredient supply.
- Efficient tableting and packaging.
- Existing regulatory approvals.
- Government tender access.
- Established pharmacy distribution.
- Portfolio economies across albendazole, pyrantel and other anti-infectives.
A manufacturer dependent on a single branded mebendazole product faces greater risk from generic substitution, wholesaler pressure and reimbursement changes.
Which companies compete in the mebendazole market?
Competition is fragmented and jurisdiction-specific. The main commercial groups include:
- Generic pharmaceutical manufacturers.
- Regional contract manufacturers.
- Public-sector suppliers.
- Branded or authorized-generic product holders.
- Companies selling combination antiparasitic portfolios.
The U.S. market has included products such as Emverm, a 100 mg chewable mebendazole tablet, alongside generic mebendazole products where available. FDA approval of Emverm in 2016 provided a modern U.S. commercial presentation for a legacy active ingredient.[4]
Competition differs materially by geography. In low- and middle-income markets, tender price, supply reliability and World Health Organization procurement eligibility can be more important than brand recognition. In the United States, pharmacy benefit design, wholesaler inventory and product availability have a greater effect on realized revenue.
What is the FDA regulatory status of mebendazole?
Mebendazole is an FDA-approved prescription antiparasitic. The FDA-approved product information identifies a 100 mg chewable dosage form for treatment of several intestinal helminth infections.[4]
Regulatory characteristics include:
- Established active ingredient.
- Conventional oral dosage form.
- No biologic manufacturing requirements.
- No biosimilar pathway.
- Abbreviated approval potential for generic products.
- Pediatric-use relevance.
- Product-specific labeling and bioequivalence requirements.
FDA approval does not guarantee persistent market availability. Products can be discontinued for commercial reasons, and a market with limited suppliers can experience shortages even when the active ingredient is old and technically straightforward to manufacture.
What is the Orange Book status of mebendazole?
The FDA Orange Book records approved drug products and, where applicable, listed patents and exclusivity information.[5] Because mebendazole is an old active ingredient, the principal regulatory issue is not new chemical entity exclusivity. The relevant questions concern product-specific patents, formulation claims, labeling, manufacturing status and whether an approved reference product has active commercial listings.
Mebendazole products may be affected by:
- Product-specific formulation patents.
- Chewable-tablet composition claims.
- Method-of-use claims.
- Patent delistings or expiration.
- Reference-listed drug status.
- Discontinued-product determinations.
- Generic approval timing.
A current Orange Book review is necessary for transaction, launch or litigation decisions because listings and marketing status can change. Historic approval of a mebendazole product does not by itself establish an active blocking patent.
What patents protect mebendazole products?
The active ingredient itself is generally not the principal exclusivity asset. Mebendazole has been known for decades, making broad composition-of-matter protection unavailable for the established antiparasitic molecule.
Potentially relevant protection can instead cover:
- Chewable tablet composition.
- Particle size or solid-state properties.
- Taste masking.
- Dissolution enhancement.
- Excipients and manufacturing processes.
- Specific dosing regimens.
- New therapeutic uses.
- Combination products.
The commercial strength of these rights depends on claim scope, expiration, prosecution history, Orange Book listing and enforceability. Formulation patents can delay direct substitution only when they are valid, listed or otherwise relevant to the proposed generic product.
How strong is the patent estate for mebendazole?
The patent estate is weak at the active-ingredient level and potentially moderate for selected branded formulations. A generic manufacturer using a materially different formulation may reduce exposure to formulation claims, although it must still satisfy FDA quality, bioequivalence and labeling requirements.
Method-of-use patents are less likely to create broad barriers in the core antiparasitic market because established labeling and clinical practice cover well-known worm infections. New-use patents for cancer or other conditions would face separate clinical, regulatory and patentability challenges.
When does mebendazole lose exclusivity?
Mebendazole lost the economic advantages associated with new chemical entity exclusivity long ago. The relevant exclusivity question is product-specific.
| Exclusivity type |
Relevance to mebendazole |
| New chemical entity exclusivity |
Not relevant to the legacy active ingredient |
| New clinical investigation exclusivity |
Possible only for qualifying new approval activity |
| New dosage-form exclusivity |
Product-specific and time-limited |
| Orphan-drug exclusivity |
Not a core feature of approved antiparasitic use |
| Pediatric exclusivity |
Possible if separately granted by FDA |
| Patent exclusivity |
Depends on formulation, use or process claims |
| Generic competition |
Possible after applicable regulatory and patent barriers expire |
For commercial forecasting, the key date is the expiration or removal of the last enforceable barrier affecting the intended generic product, not the historical introduction date of mebendazole.
Which companies are challenging mebendazole exclusivity?
Mebendazole is not generally associated with a major current Paragraph IV litigation campaign comparable to high-value branded medicines. Generic competition is more likely to arise through ordinary abbreviated new drug application filings, product discontinuations, manufacturing transfers and market-entry decisions.
A Paragraph IV challenge would require a generic applicant to certify that a listed patent is invalid, unenforceable or not infringed. The commercial incentive depends on:
- Expected market size.
- Price of the reference product.
- Number of existing suppliers.
- Remaining patent term.
- Litigation cost.
- Probability of a first-filer advantage.
- Ability to obtain acceptable product margins.
Because the underlying market is relatively small, litigation may be unattractive unless the branded product has a substantial price premium or the formulation patent covers a commercially important presentation.
What formulation patents protect mebendazole?
The most commercially relevant formulation issues involve chewability, palatability, dissolution and dose uniformity. Mebendazole has low aqueous solubility, so formulation design can affect product performance and manufacturing cost.
A formulation patent may have value if it:
- Claims a narrow but commercially necessary excipient system.
- Produces a measurable dissolution or stability advantage.
- Supports pediatric acceptability.
- Is difficult to design around without sacrificing bioequivalence.
- Is listed against an FDA reference product.
Formulation patents are less powerful when generic companies can use different excipients, compression conditions or manufacturing steps while maintaining equivalent clinical performance.
What generic entry risks exist for mebendazole?
Generic entry risk is high at the molecule level and moderate at the product level. The main risk to a branded mebendazole product is substitution by lower-priced tablets or chewables once a competing product is approved and commercially supplied.
| Risk |
Impact |
| Multiple ANDA approvals |
High price erosion |
| Single-source generic market |
Moderate pricing power for incumbent |
| Supplier discontinuation |
Temporary supply disruption |
| Public-sector tender loss |
Volume decline |
| Formulation differentiation |
May preserve a limited price premium |
| New-use development |
Low probability without clinical success |
| Manufacturing failure |
High short-term availability risk |
The most likely launch scenario is a low-price generic entering through pharmacy and institutional channels, followed by reimbursement substitution and declining branded share. A second scenario is a fragmented market in which approvals exist but few suppliers actively commercialize the product. In that case, prices may remain volatile rather than steadily declining.
What patent litigation affects mebendazole?
Mebendazole does not have a widely publicized, high-value patent litigation profile in the manner of major oncology, immunology or metabolic drugs. Litigation exposure is more likely to arise from:
- Formulation patents.
- ANDA Paragraph IV notices.
- Trademark disputes.
- Distribution agreements.
- Product liability claims.
- Manufacturing and supply contracts.
Patent litigation should be evaluated at the specific product and jurisdiction level. A U.S. dispute involving a chewable formulation would not automatically affect tablet products in Europe, India, Latin America or African procurement markets.
How does mebendazole compare with albendazole?
| Factor |
Mebendazole |
Albendazole |
| Drug class |
Benzimidazole |
Benzimidazole |
| Main use |
Intestinal helminths |
Intestinal helminths and broader tissue infections |
| Dosage forms |
Often 100 mg chewable |
Commonly 400 mg tablet or chewable |
| Market role |
Retail and public-health deworming |
Public-health, clinical and broader antiparasitic use |
| Innovation profile |
Mature generic |
Mature generic |
| Competition |
Generic and regional |
Generic and regional |
| Financial outlook |
Stable, low-value |
Broader demand potential |
| Biosimilar risk |
None |
None |
Albendazole may have a broader commercial profile in some markets because of its use in additional parasitic diseases. Mebendazole remains competitive where its dosing, tolerability, price and procurement availability are favorable.
What licensing deals affect mebendazole?
Mebendazole is more likely to be commercialized through distribution, contract manufacturing and regional licensing arrangements than through major royalty-bearing innovation licenses. Publicly visible deal activity is limited compared with newer pharmaceutical products.
Relevant transaction structures include:
- Regional commercialization rights.
- Authorized-generic arrangements.
- Contract manufacturing agreements.
- Government supply contracts.
- Nonprofit procurement agreements.
- Portfolio acquisitions involving several generic products.
The value of a licensing deal depends on regulatory approvals, supply reliability, market exclusivity, tender history and the ability to maintain margins after wholesaler and payer discounts.
What revenue exposure do pharmaceutical companies have to mebendazole?
Revenue exposure is usually modest because companies rarely disclose mebendazole sales separately. It is generally part of a broader generic or anti-infective portfolio.
Financial exposure can still be material for a small manufacturer if mebendazole represents a high share of:
- Pediatric prescription revenue.
- Public-sector tender volume.
- Regional anti-infective sales.
- Manufacturing capacity.
- Distributor contracts.
For large pharmaceutical companies, mebendazole is unlikely to affect consolidated revenue materially. For a niche generic company, the product can support recurring cash flow but creates concentration risk if a tender is lost or a supplier exits.
What is the long-term commercial outlook for mebendazole?
The base case is stable unit demand, low nominal price growth and continuing generic pressure. Revenue upside is most plausible in emerging markets with expanding diagnosis and government deworming programs. Margin upside is limited unless a company secures a temporary supply advantage, differentiated formulation or favorable procurement contract.
The principal downside risks are:
- Public-sector price compression.
- Increased use of albendazole or pyrantel.
- Generic substitution.
- Manufacturing interruptions.
- Regulatory discontinuation.
- Reduced institutional funding.
- Product commoditization.
The strongest commercial strategy is a low-cost, reliable supply model supported by multiple markets and complementary antiparasitic products. A strategy based solely on premium pricing or speculative repurposing has a weaker probability of producing durable returns.
Key Takeaways
- Mebendazole is a mature generic anthelmintic with recurring public-health demand.
- No single audited global revenue figure is publicly established.
- Financial growth is more likely to come from volume and geographic expansion than price increases.
- The molecule has no meaningful new chemical entity exclusivity remaining.
- Formulation, method-of-use and manufacturing patents may affect specific products, but they do not create broad molecule-level protection.
- Generic entry risk is high, particularly for conventional 100 mg tablets and chewable products.
- The market has no biosimilar risk because mebendazole is a small molecule.
- Public procurement, supply reliability and manufacturing cost are central commercial variables.
- Mebendazole has greater strategic value in a diversified antiparasitic portfolio than as a standalone premium product.
- Long-term revenue is likely to remain stable or modestly growing, while margins remain under pressure.
FAQs About Mebendazole Market and Financial Outlook
Is mebendazole a profitable pharmaceutical product?
It can be profitable for a low-cost manufacturer with efficient production and reliable tender access. Its low price and generic competition limit premium margins.
Does mebendazole have biosimilar competition?
No. Mebendazole is a chemically synthesized small-molecule drug, so competing products are generics rather than biosimilars.
Can a new mebendazole formulation receive patent protection?
Yes. A novel formulation, delivery system, manufacturing process or approved therapeutic use may qualify for patent protection if it meets applicable patentability requirements.
Is mebendazole used in global deworming programs?
Yes. Mebendazole is used in treatment and mass drug administration programs for soil-transmitted helminth infections, subject to national policies and procurement decisions.[2]
Could mebendazole become a major oncology drug?
That outcome is not established. Repurposing research has generated interest, but a major oncology market would require successful clinical trials, regulatory approval, physician adoption and reimbursement.
References
-
World Health Organization. (2023). WHO model list of essential medicines, 23rd list. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02
-
World Health Organization. (2023). Soil-transmitted helminth control in children: Progress report and related guidance. https://www.who.int/teams/control-of-neglected-tropical-diseases
-
National Cancer Institute. (n.d.). Mebendazole. NCI Drug Dictionary. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mebendazole
-
U.S. Food and Drug Administration. (2016). EMVERM- mebendazole tablet, chewable prescribing information. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
